Cargando…

Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection

Because prolonged viral replication of SARS-CoV-2 is increasingly being recognized among immunocompromised patients, subacute or chronic COVID-19 pneumonia can cause persistent lung damage and may lead to viral escape phenomena. Highly efficacious antiviral therapies in immunosuppressed hosts with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Daiki, Nakamori, Yasushi, Maruyama, Shuhei, Shimazu, Haruka, Saito, Fukuki, Yoshiya, Kazuhisa, Kuwagata, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462070/
https://www.ncbi.nlm.nih.gov/pubmed/36085172
http://dx.doi.org/10.1186/s40164-022-00307-9
_version_ 1784787096440930304
author Wada, Daiki
Nakamori, Yasushi
Maruyama, Shuhei
Shimazu, Haruka
Saito, Fukuki
Yoshiya, Kazuhisa
Kuwagata, Yasuyuki
author_facet Wada, Daiki
Nakamori, Yasushi
Maruyama, Shuhei
Shimazu, Haruka
Saito, Fukuki
Yoshiya, Kazuhisa
Kuwagata, Yasuyuki
author_sort Wada, Daiki
collection PubMed
description Because prolonged viral replication of SARS-CoV-2 is increasingly being recognized among immunocompromised patients, subacute or chronic COVID-19 pneumonia can cause persistent lung damage and may lead to viral escape phenomena. Highly efficacious antiviral therapies in immunosuppressed hosts with COVID-19 are urgently needed. From February 2022, we introduced novel treatment combining antiviral therapies and neutralizing antibodies with frequent monitoring of spike-specific antibody and RT-PCR cycle threshold (Ct) values as indicators of viral load for immunocompromised patients with persistent COVID-19 infection. We applied this treatment to 10 immunosuppressed patients with COVID-19, and all completed treatment without relapse of infection. This may be a potentially successful treatment strategy that enables us to sustain viral clearance, determine optimal timing to stop treatment, and prevent virus reactivation in immunocompromised patients with persistent COVID-19.
format Online
Article
Text
id pubmed-9462070
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94620702022-09-10 Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection Wada, Daiki Nakamori, Yasushi Maruyama, Shuhei Shimazu, Haruka Saito, Fukuki Yoshiya, Kazuhisa Kuwagata, Yasuyuki Exp Hematol Oncol Correspondence Because prolonged viral replication of SARS-CoV-2 is increasingly being recognized among immunocompromised patients, subacute or chronic COVID-19 pneumonia can cause persistent lung damage and may lead to viral escape phenomena. Highly efficacious antiviral therapies in immunosuppressed hosts with COVID-19 are urgently needed. From February 2022, we introduced novel treatment combining antiviral therapies and neutralizing antibodies with frequent monitoring of spike-specific antibody and RT-PCR cycle threshold (Ct) values as indicators of viral load for immunocompromised patients with persistent COVID-19 infection. We applied this treatment to 10 immunosuppressed patients with COVID-19, and all completed treatment without relapse of infection. This may be a potentially successful treatment strategy that enables us to sustain viral clearance, determine optimal timing to stop treatment, and prevent virus reactivation in immunocompromised patients with persistent COVID-19. BioMed Central 2022-09-09 /pmc/articles/PMC9462070/ /pubmed/36085172 http://dx.doi.org/10.1186/s40164-022-00307-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Wada, Daiki
Nakamori, Yasushi
Maruyama, Shuhei
Shimazu, Haruka
Saito, Fukuki
Yoshiya, Kazuhisa
Kuwagata, Yasuyuki
Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection
title Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection
title_full Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection
title_fullStr Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection
title_full_unstemmed Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection
title_short Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection
title_sort novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent covid-19 infection
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462070/
https://www.ncbi.nlm.nih.gov/pubmed/36085172
http://dx.doi.org/10.1186/s40164-022-00307-9
work_keys_str_mv AT wadadaiki noveltreatmentcombiningantiviralandneutralizingantibodybasedtherapieswithmonitoringofspikespecificantibodyandviralloadforimmunocompromisedpatientswithpersistentcovid19infection
AT nakamoriyasushi noveltreatmentcombiningantiviralandneutralizingantibodybasedtherapieswithmonitoringofspikespecificantibodyandviralloadforimmunocompromisedpatientswithpersistentcovid19infection
AT maruyamashuhei noveltreatmentcombiningantiviralandneutralizingantibodybasedtherapieswithmonitoringofspikespecificantibodyandviralloadforimmunocompromisedpatientswithpersistentcovid19infection
AT shimazuharuka noveltreatmentcombiningantiviralandneutralizingantibodybasedtherapieswithmonitoringofspikespecificantibodyandviralloadforimmunocompromisedpatientswithpersistentcovid19infection
AT saitofukuki noveltreatmentcombiningantiviralandneutralizingantibodybasedtherapieswithmonitoringofspikespecificantibodyandviralloadforimmunocompromisedpatientswithpersistentcovid19infection
AT yoshiyakazuhisa noveltreatmentcombiningantiviralandneutralizingantibodybasedtherapieswithmonitoringofspikespecificantibodyandviralloadforimmunocompromisedpatientswithpersistentcovid19infection
AT kuwagatayasuyuki noveltreatmentcombiningantiviralandneutralizingantibodybasedtherapieswithmonitoringofspikespecificantibodyandviralloadforimmunocompromisedpatientswithpersistentcovid19infection